Immuneering’s (IMRX) “Buy” Rating Reiterated at Needham & Company LLC

Needham & Company LLC reaffirmed their buy rating on shares of Immuneering (NASDAQ:IMRX) in a research note released on Monday,Benzinga reports. They currently have a $15.00 price target on the stock.

Other equities analysts have also issued reports about the stock. Chardan Capital restated a “buy” rating and issued a $13.00 price objective on shares of Immuneering in a report on Wednesday, January 8th. Morgan Stanley lowered Immuneering from an “equal weight” rating to an “underweight” rating in a report on Friday, December 13th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat, Immuneering has an average rating of “Hold” and an average target price of $12.80.

Immuneering Stock Performance

NASDAQ:IMRX opened at $1.90 on Monday. The firm has a 50-day simple moving average of $2.05 and a two-hundred day simple moving average of $1.79. Immuneering has a fifty-two week low of $1.00 and a fifty-two week high of $7.68.

Institutional Investors Weigh In On Immuneering

Hedge funds have recently added to or reduced their stakes in the stock. Vontobel Holding Ltd. bought a new stake in shares of Immuneering in the third quarter worth $25,000. Corsair Capital Management L.P. purchased a new position in Immuneering in the third quarter worth about $25,000. Point72 Asia Singapore Pte. Ltd. purchased a new position in Immuneering in the second quarter worth about $44,000. XTX Topco Ltd grew its stake in shares of Immuneering by 37.3% during the 2nd quarter. XTX Topco Ltd now owns 34,159 shares of the company’s stock valued at $44,000 after purchasing an additional 9,274 shares during the period. Finally, Acadian Asset Management LLC purchased a new stake in shares of Immuneering during the 2nd quarter valued at about $67,000. 67.65% of the stock is currently owned by hedge funds and other institutional investors.

About Immuneering

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors.